Chief
Executive Officer
Dr. Giorgio Roscigno |
 |
Dr. Roscigno has 20 years experience in the pharmaceutical industry in medical and clinical research of antinfectives. He joined the industry after 5 years’ field medical practice in Ethiopia, Sudan and the Democratic Republic of Congo. Dr. Roscigno has been, at different times, Medical Director for Africa, Asia, and Europe, the European Clinical Research Director for Antinfectives, and finally the International Medical Director for Antinfectives with Aventis in Paris, France.
During his years with industry, Dr. Roscigno was closely associated with the clinical work and the subsequent registration (including FDA) of all the tuberculosis (TB) fixed-dose combinations containing rifampin. He also contributed to the clinical development of rifapentine, a long acting rifamycin approved by the FDA in 1998.
Dr. Roscigno has led the clinical research work on DFMO eflornithine for the treatment of sleeping sickness, and the coordination of the African multicenter clinical trial in collaboration with the WHO Special Programme for Research & Training in Tropical Diseases (TDR). The outcome of this trial represented the clinical package for FDA approval in 1992.
In 2000, Dr. Roscigno was among the founding members of the Global Alliance for TB Drug Development (GATB), a non-profit public-private partnership dedicated to the discovery of new tuberculosis drugs. He left the industry and joined the GATB, initially as Acting Chief Executive Officer, and later as Strategic Development Director.
In May 2003, Dr. Roscigno joined FIND as Chief Executive Officer.
Contact:
giorgio.roscigno@finddiagnostics.org
|
